Phase 1 N=124 A Study of TAK-510 in Healthy Adults
Healthy Participants
Primary: Parts 1 and 2: Number of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=47 A Study of GFH018 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Incidence of Dose-limiting Toxicity (DLT) Events — 0; 0; 0; 0 Participants
Phase 1 N=32 PF-04634817 Renal Impairment Study
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
Phase 1 N=96 A Study of Soticlestat Tablets in Healthy Adults
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Soticlestat — 1762; 1428; 1708; 1509 nanogram per milllilitre (ng/ml)
Phase 1 N=60 A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Contraception
Primary: Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone Acetate (MPA) — 0.940; 1.180; 1.750; 0.963 nanograms (ng)/ milliliter (mL)
Phase 1 N=156 Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Solid Tumors · Lymphoma
Primary: Part 1: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0) — 15.1…
Phase 1 N=28 A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 23.92; 25.20…
Phase 1 N=24 Phase I/Ib Multiple Ascending Dose Study in China
Metastatic Solid Tumors
Primary: Number of Participants With of Dose-limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version…
Phase 1 N=39 Healthy Combine Study
Healthy
Primary: Change in Intact FGF23 — 1.001; 1.006; 1.009; 1.005 pg/ml — p=0.3738
Phase 1 N=18 A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Healthy
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With…
Phase 1 N=18 Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Neutropenia · Breast Cancer
Primary: Evaluate the Safety of F-627 for Injection in the Treatment of Female Postoperative Patients With Breast Cancer Who Require Adjuvant Chemotherapy. — 6; 6; 6; 6…
Phase 1 N=48 A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Percentage of Participants
Phase 1 N=14 A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 124.15; 215.66 Nanomoles *…
Phase 1 N=13 A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food
Healthy
Primary: Area Under the Concentration-time Curve of BI 1595043 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — NA; NA hour*nanomol/Liter
Phase 1 N=63 This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 6.7; 50.0; 33.3; 0.0 Percentage of participants